You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复宏汉霖(02696.HK)PD-1联合化疗治疗肺癌3期临床研究完成土耳其首例患者给药
格隆汇 04-22 19:40

格隆汇4月22日丨复宏汉霖(02696.HK)公告,近日,公司比较重组抗PD-1人源化单克隆抗体注射液(HLX10)联合化疗(卡铂-白蛋白紫杉醇)与化疗(卡铂-白蛋白紫杉醇)一线治疗局部晚期或转移性鳞状非小细胞肺癌的3期临床研究完成土耳其首例患者给药。2019年8月,该临床研究已于中国境内完成首例患者给药。

该项研究为一项比较HLX10联合化疗(卡铂-白蛋白紫杉醇)与化疗(卡铂-白蛋白紫杉醇)一线治疗局部晚期或转移性鳞状非小细胞肺癌的随机、双盲、国际多中心3期临床研究,目的在于比较两组之间的临床疗效和安全性。

该候选药物为公司自主研发的创新型治疗用生物制品,拟用于实体瘤治疗,目前正进一步探索用于治疗慢性B型肝炎(即慢性乙型肝炎)的可能性。

截至本公告日,于全球范围内上市的靶向PD-1的单克隆抗体药品包括默沙东制药有限公司的可瑞达、美国百时美施贵宝公司的欧狄沃、信达生物制药(苏州)有限公司的达伯舒等。根据IQVIA MIDASTM提供的资料,2019年度,靶向PD-1的单克隆抗体药品于全球范围内的销售额约为187.41亿美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account